BLACK DIAMOND THERAPEUTICS INC. - COMMON STOCK

Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

01 Jun 2024 09:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

29 May 2024 07:00:01 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

09 May 2024 06:30:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces Changes to Board of Directors

11 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting

07 Apr 2024 17:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

03 Apr 2024 07:00:01 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

12 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024

05 Mar 2024 15:30:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

28 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones

04 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM

13 Dec 2023 06:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

07 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

06 Nov 2023 06:45:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

14 Oct 2023 11:30:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

04 Oct 2023 11:14:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces CEO Transition

18 Sep 2023 06:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer

11 Sep 2023 07:00:01 By Nasdaq GlobeNewswire

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

05 Sep 2023 07:00:01 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

11 Aug 2023 06:30:00 By Nasdaq GlobeNewswire